Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses

Yan Bi1, Xiubin Li2, Daizhi Yang3, Yuantao Hao4, Hua Liang3, Dalong Zhu1*, Jianping Weng3*

ABSTRACT

Aims/Introduction: Although long-acting insulin analogs are recommended in type 2 diabetics failing on oral agents, their efficacy is uncertain. Here we compared the efficacy and safety of regimens based on long-acting insulin analogs with other preparations in insulin-naïve type 2 diabetics failing on oral agents.

Materials and Methods: Data from 9548 participants in 22 English studies were included. Most of the studies were of short to medium duration and of low quality.

Results: In terms of decreasing hemoglobin A1c, long-acting insulin analogs were not statistically significant to rapid-acting insulin analogs or intermediate neutral protamine Hagedorn (NPH) insulin or glucagon-like peptide-1 (GLP-1) analogs, and the differences between long-acting and biphasic insulin analogs were marginal. Compared with rapid-acting insulin analogs, long-acting insulin analogs were similar in the incidence of total hypoglycemia, and the superiority in less weight gain was inconsistent. Relative to biphasic insulin analogs, long-acting insulin analogs were associated with lower incidence of total hypoglycemia and less weight gain. Compared with NPH insulin, long-acting insulin analogs were associated with lower incidence of total and nocturnal hypoglycemia. Relative to GLP-1 analogs, long-acting insulin analogs were associated with lower incidence of treatment related adverse events but with greater weight gain.

Conclusions: For type 2 diabetics failing on oral agents, initiating long-acting insulin analogues seems to provide glycemic control similar to rapid-acting insulin analogs or NPH insulin or glucagon-like peptide-1 analogs and slightly inferior to biphasic insulin analogs with fewer side-effects.

KEY WORDS: Long-acting insulin analogs, Meta-analysis, Type 2 diabetes

INTRODUCTION

The landmark prospective randomized clinical trials (RCT) from the UK Prospective Diabetes Study (UKPDS) showed that improving glycemic control, as assessed by hemoglobin A1c (HbA1c) levels, reduces the risks of complications in type 2 diabetes1–3. To achieve adequate glycemic control, many type 2 diabetics after failing on oral hypoglycemic agents (OHA) will eventually require insulin therapy as deterioration of β-cell function and loss of β-cell mass progresses over time4,5. Recent American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus statements recommend the early initiation of basal insulin therapy as a result of their simplicity and feasibility, combined with OHA in patients not achieving acceptable glucose control6. The two available long-acting insulin analogs, including insulin glargine and insulin detemir, have been designed to provide more consistent, relative flat and protracted basal insulin levels than intermediate-acting insulin7.

However, there is a general uncertainty as to whether basal insulin based on regimens will help as many patients achieve glycemic control as biphasic insulin and rapid-acting insulin preparations based on regimens8,9. Initial 1-year data from the Treating-to-Target in Type 2 diabetes (4-T) study showed that less than one-third of patients who were assigned to receive the long-acting insulin analog to oral therapy reached a HbA1c level below the recommended 7% target, which was lower than that of the biphasic and rapid-acting insulin analog10. Previous meta-analyses studies found that HbA1c reduction might be obtained in type 2 diabetes when insulin is initiated with biphasic or
prandial insulin regimens rather than basal regimens. Nevertheless, after those publications, further results after 3-year follow-up from the 4-T study have been published, in which they reported patients who added to a long-acting insulin analog or rapid-acting insulin analog-based regimens achieved better glycemic control than a biphasic insulin analog-based regimen. Therefore, the optimal insulin regimen to start with when OHA fails to control glucose in type 2 diabetes is far more uncertain. In the present study, we present up-to-date data from a systemic review and meta-analyses of RCT, which aimed to assess the comparative effectiveness and safety of regimens based on long-acting insulin analogs compared with other injectable preparations in insulin-naive patients with type 2 diabetes failing on oral agents.

**MATERIALS AND METHODS**

**Inclusion and Exclusion Criteria**

We included RCT if they reported data for comparing long-acting insulin analog-based regimens vs one of the following injectable agents-based regimens – rapid-acting insulin analogs, or biphasic insulin analogs, or NPH insulin, or glucagon-like peptide-1 (GLP-1) analogs – with a duration of 12 weeks or longer, and recruited insulin-naive adults (>18 years) with type 2 diabetes inadequately controlled with oral agents. Pooled analyses on human biphasic insulin or intermediate-acting insulin analog were not possible, because only one study for each comparison was reported. We limited the research to English-language studies; non-English-language studies were excluded, because the quality of these studies is difficult to evaluate. If we identified more than one publication of an original study, we assessed those articles together to maximize data collection. Citations were excluded if: (i) the intervention time was <12 weeks; (ii) the use of OHA was unbalanced between study arms; (iii) they related to type 1 diabetes; or (iv) there was a history of insulin treatment.

**Outcome Measures**

In the present study, we present results for intermediate clinical outcomes of HbA1c; fasting glucose; postprandial glucose; weight gain; daily insulin dose by bodyweight; the incidence of total, nocturnal and severe hypoglycemia; and the incidence of any adverse events, treatment-related adverse events and withdrawal as a result of adverse events.

**Search Strategy**

We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (1980 to March 2010) to identify relevant RCT trials using terms of type 2 diabetes, long-acting insulin, detemir or levemir, glargine or lantus.

**Data Extraction and Study Quality Assessment**

Two investigators independently reviewed relevant publications and abstracted the data, and any disagreements were resolved by consensus and discussion with a third reviewer. Methodological quality was assessed using criteria set out by Jadad, with an additional point given if the analysis was by intention-to-treat.

**Data Synthesis and Statistical Analysis**

Data were combined using a random-effects model (Review Manager Version 4.2.10; The Cochrane Collaboration, Copenhagen, Denmark). For the evaluation of outcomes, we combined parallel and crossover trials, because no crossover studies reported carryover effects. Data from intention-to-treat studies were recorded after intention-to-treat principles.

For the evaluation of outcomes of HbA1c, fasting, postprandial glucose and weight gain, the changes between baseline and end-point were used for the comparisons between groups. Standard deviation (SD) was recorded from studies or calculated from the baseline, and final SD using a correlation of 0.5 or from 95% confidence intervals (CI) and P-values for the difference in means (Cochrane Collaboration, 2004). Definitions of hypoglycemia varied among studies (Table 1). The most consistently reported measure of hypoglycemia was the percentage of participants experiencing an episode of a specific type of hypoglycemia (symptomatic, asymptomatic, nocturnal and severe). Therefore, we chose to combine this measure by calculating the incidence of participants experiencing an episode of a specific type for each intervention as an overall indicator of hypoglycemia.

Continuous outcomes were calculated by weighted mean differences (WMD) with 95% CI. Dichotomous outcomes were summarized as odds ratio (OR) with 95% CI. We determined heterogeneity by using an I² statistic, and we carried out subgroup analysis for: (i) baseline HbA1c (<9%, ≥9%; as the failure criteria used in different studies); (ii) quality score (<3, ≥3); (iii) variation in study length; (iv) oral agents given as added-on therapy (yes or not) or the nature of the oral agents used in combination with insulin; and (v) long-acting insulin analogs (glargine, detemir). We carried out sensitivity analyses to determine whether inclusion of studies deemed to be of low methodological quality affected the results. Funnel plots were used to assess the potential for publication bias and small sample size.

**RESULTS**

**Study Characteristics**

In total, data from 9548 participants in 22 RCT studies were included (Figure 1). A total of 19 were parallel groups and three were crossovers. A total of 17 studies were analyzed according to intention-to-treat principles. A total of 15 studies described randomization methods. No study was double-blinded. The median quality score of included studies was 3. The study participants had a mean age of 57.7 years, mean body mass index of 30.1 kg/m², mean duration of diabetes of 9.0 years, and 55.6% were male. The median duration of follow up was 34 weeks, and average study size was 434 participants. Participants had a median HbA1c level of 8.8%, and median fasting plasma glucose of 10.9 mmol/L. A total of 20 studies...
### Table 1 | Characteristics of included studies

| Study description | Author, Year, Reference | Groups | Study length (weeks) | Patients (n) | Men (%) | Mean age (years) | Mean BMI (kg/m²) | Diabetes duration (years) | Start HbA₁c (%) | Start FPG (mmol/L) | Hypoglycemia (<mmol/L) | Previous treatment | Quality score |
|-------------------|-------------------------|--------|----------------------|--------------|---------|-----------------|------------------|-------------------------|----------------|-----------------|------------------------|-------------------|---------------|
| Long-acting insulin analogs vs rapid-acting insulin analogs | Holman 2009¹¹ | Detemir vs aspart, SU was replaced by second insulin if necessary | 148 | 473 | 62.4 | 61.8 | 297 | 9 | 85 | 96 | 3.1 | MET+SU | 4 |
| | Bretzel 2008¹⁶ (intention-to-treat) | Glargine vs lispro, both plus previous OHA | 44 | 377 | 57 | 59.7 | 2925 | 8.85 | 87 | 101 | 3.3 | MET/SU/TZD/α-Glucosidase inhibitors | 4 |
| | Kazda 2006¹⁶ | Glargine vs lispro | 24 | 105 | 52.5 | 59.8 | 304 | 5.4 | 82 | 97 | 3 | MET/SU/TZD/α-Glucosidase inhibitors/Glinides | 3 |
| Long-acting insulin analogs vs biphasic insulin analogs | Holman 2009¹¹ | Detemir vs BIAsp70/30, SU was replaced by second insulin if necessary | 148 | 469 | 64.5 | 61.8 | 300 | 9 | 85 | 96 | 3.1 | MET+SU | 4 |
| | Kazda 2006¹⁶ | Glargine vs lisproMix50/50 | 24 | 107 | 51.4 | 58.9 | 301 | 5.7 | 81 | 95 | 3 | MET/SU/TZD/α-Glucosidase inhibitors/Glinides | 3 |
| | Strojek 2009¹⁷ (intention-to-treat)¹⁶ | Glargine vs BIAsp70/30, plus MET + SU | 26 | 469 | 43.9 | 56 | 291 | 9.3 | 85 | — | 3.1 | MET/SU | 3 |
| | Buse 2009¹⁸ (intention-to-treat) | Glargine vs lisproMix 75/25, plus previous OHA | 24 | 2091 | 52.8 | 57 | 32 | 9.5 | 905 | 108 | 3.9 | MET/SU/TZD | 3 |
| | Raskin 2005¹⁹ (intention-to-treat) | Glargine vs BIAspart 70/30, plus MET | 28 | 233 | 54.5 | 52.4 | 315 | 9.2 | 977 | 138 | 3.1 | MET/other agents | 3 |
| | Malone 2004²⁰ (crossover) (intention-to-treat) | Glargine vs lisproMix 75/25, plus MET | 16 | 105 | 62.9 | 55 | 304 | 8.95 | 87 | 85 | 3.5 | MET/SU/Glinides/α-Glucosidase inhibitors/TZD | 4 |
| | NCT00377858²¹ (intention-to-treat) | Glargine plus lispro vs lisproMix | 36 | 479 | 476 | 59 | 293 | 11.3 | 947 | — | 3.9 | Two or thee OHA | 3 |
| Long-acting insulin analogs vs intermediate-acting human NPH insulin | De Mattia 2009²² (crossover) | Glargine vs NPH, plus previous OHAs | 24 | 20 | 70 | 59.4 | 295 | — | 93 | 11.3 | — | MET+SU | 2 |
| | Pan 2007²³ | Glargine vs NPH, plus SU | 24 | 443 | 42.5 | 56.1 | 2495 | 1015 | 9035 | 125 | 28 | SU + other OHA | 2 |
| | Blaschewitz 2006²⁴ | Glargine vs NPH, plus SU | 24 | 481 | 40.5 | 56.6 | 2725 | 10.55 | 915 | 11.1 | 28 | SU/MET/α-Glucosidase inhibitor | 2 |
| | Yki-Jarvinen 2006²⁵ (intention-to-treat) | Glargine vs NPH, plus MET | 36 | 110 | 63.5 | 56.5 | 31.65 | 9 | 955 | 13 | 4 | MET/SU | 4 |
| Author, Year, Reference | Groups | Study length (weeks) | Patients (n) | Men (%) | Mean age (years) | Mean BMI (kg/m²) | Diabetes duration (years) | Start HbA₁c (%) | Start FPG (mmol/L) | Hypoglycemia (<mmol/L) | Previous treatment | Quality score |
|-------------------------|--------|---------------------|-------------|---------|----------------|-----------------|-------------------------|----------------|----------------|---------------------|------------------|--------------|
| Philips-Tsimikas 2006²⁶ (intention-to-treat) | Detemir vs NPH, plus previous OHA | 20 | 333 | 568 | 58.5 | 30 | 10.3 | 9.04 | 11.1 | 3.1 | MET/SU/TZD/α-Glucosidase inhibitor | 4 |
| Hermansen 2006²⁷ (intention-to-treat) | Detemir vs NPH, plus previous OHA | 24 | 475 | 53.1 | 60.9 | 29.0 | 9.7 | 856 | 11 | 4 | MET/SU/α-Glucosidase inhibitor | 4 |
| Riddle 2003²⁸ (intention-to-treat) | Glargine vs NPH, plus previous OHA | 24 | 756 | 55.5 | 55.5 | 32.35 | 8.7 | 859 | 109 | 4 | MET/SU/MET/TZD | 4 |
| Fritsche 2003²⁹ (intention-to-treat) | Glargine vs NPH, plus SU | 28 | 459 | 53.7 | 61 | 28.7 | 88 | 91 | 121 | 4.2 | SU/MET/α-Glucosidase inhibitor | 4 |
| Yki-Jarvinen 2000³⁰ (intention-to-treat) | Glargine vs NPH, plus previous OHA | 52 | 422 | 54 | 59 | 28.9 | 10 | 9 | _ | 2.8 | MET/SU/α-Glucosidase inhibitor | 4 |

**Table 1** | (Continued) | Groups | Study length (weeks) | Patients (n) | Men (%) | Mean age (years) | Mean BMI (kg/m²) | Diabetes duration (years) | Start HbA₁c (%) | Start FPG (mmol/L) | Hypoglycemia (<mmol/L) | Previous treatment | Quality score |
|-------------------------|--------|---------------------|-------------|---------|----------------|-----------------|-------------------------|----------------|----------------|---------------------|------------------|--------------|
| Long-acting insulin analogs vs GLP-1 analogs | Davies 2009³¹ (intention-to-treat) | Glargine vs exenatide, plus previous OHA | 26 | 234 | 68.4 | 56.5 | 34.1 | 87 | 857 | 105 | 3.4 | MET/SU/TZD | 3 |
| | Bunck 2009³² (intention-to-treat) | Glargine vs exenatide, plus MET | 52 | 69 | 65.3 | 58.4 | 30.5 | 485 | 7.5 | 92 | 3.3 | MET | 3 |
| | Russell-Jones³³ (intention-to-treat) | Glargine vs lixisnide, plus MET + SU | 26 | 462 | 58.5 | 57.6 | 30.4 | 95 | 83 | 91 | 3.1 | MET/SU | 4 |
| | Barnett 2007³⁴ (crossover) (intention-to-treat) | Glargine vs exenatide, plus previous OHA | 16 | 114 | 47.1 | 54.9 | 31.1 | 74 | 895 | 121 | 3.3 | MET/SU | 4 |
| | Heine 2005³⁵ (intention-to-treat) | Glargine vs exenatide, plus previous OHA | 26 | 549 | 55.8 | 58.9 | 31.4 | 9.55 | 8.25 | 103 | 3.4 | MET + SU | 4 |

BMI, body mass index; GLP-1, glucagon-like peptide-1; MET, metformin; NPH, neutral protamine Hagedorn; NPL, neutral protamine Lispro; OHA, oral hypoglycemic agent; SU, sulfonylurea; TZD, thiazolidinedione.

*Standard deviation of difference between baseline and end of study was calculated according to the approach indicated in Cochrane Collaboration, 2004 (http://www.cochrane-net.org).
included the use of oral glucose-lowering medications in conjunction with insulin (Table 1).

**Long-acting Insulin Analogs vs Rapid-acting Insulin Analogs**

Pooling studies showed that long-acting insulin analogs were not statistically significant to rapid-acting insulin analogs in decreasing HbA1c (WMD 0.32%, 95% CI 0.02 to 0.65), but this varied between studies ($I^2 = 75.3%$; Figure 2a)11,15,16. Heterogeneity was substantially reduced when a study with shorter diabetes duration and lower baseline HbA1c was removed (WMD 0.14%, 95% CI 0.02 to 0.29; $I^2 = 0%$)16. The SD for the change in one study were imputed from baseline and final SD15.

**Fasting Glucose and Postprandial Glucose**

Pooling studies showed that long-acting insulin analogs were not statistically significant to rapid-acting insulin analogs in decreasing fasting glucose (WMD –1.36 mmol/L, 95% CI –3.21 to 0.49), but with high heterogeneity ($I^2 = 97.2%$), which was not explained by baseline HbA1c levels or combination therapy of OHA or treatment targets11,15,16. However, long-acting insulin analogs were less effective than rapid-acting insulin analogs in decreasing morning postprandial glucose (WMD 0.78 mmol/L, 95% CI 0.38–1.19) with no heterogeneous ($I^2 = 5.3%$; Table 2)11,15,16.

**Weight Gain**

Pooling citations showed that, compared with rapid-acting insulin analogs, long-acting insulin analogs were significantly associated with less weight gain (WMD –1.57 kg, 95% CI –3.01 to –0.13), but with heterogeneity ($I^2 = 73.3%$; Table 2)11,15,16. However, subgroup analysis after removing a study with longer study length and the use of detemir as the comparator did not show statistical differences between the two groups with no heterogeneity (WMD –0.77 kg, 95% CI –1.55 to 0.01; $I^2 = 20.3%$)11.

**Daily Insulin Dose by Bodyweight**

Pooling studies showed no significant differences in daily insulin dosages between rapid-acting insulin analogs and long-acting insulin analogs (WMD –0.01 IU/kg per day, 95% CI –0.16 to 0.14), but with heterogeneity ($I^2 = 59.7%$; Table 2)11,16.

**Hypoglycemia**

Pooling studies showed no significant difference in incidence of total hypoglycemia between long-acting and rapid-acting insulin analogs (OR 0.23, 95% CI 0.05–1.13), but with heterogeneity ($I^2 = 91.2%$), which was not explained by baseline HbA1c levels or combination therapy of OHA or two long-acting insulin analogs (Table 2)11,15,16. Pooled analysis on severe hypoglycemia or nocturnal hypoglycemia was not possible as a result of insufficient data. Two citations11,15 reported no significant differences in rates of severe hypoglycemia and one citation15 observed no significant differences in rates of nocturnal hypoglycemia between two treatment arms.

**Adverse Events**

Pooling studies showed no significant difference in any adverse events between long-acting and rapid-acting insulin analogs.
(OR 1.51, 95% CI 0.65–3.5), but with heterogeneity ($I^2 = 65\%$), which was not explained by baseline HbA1c levels or combination therapy of OHA, or one form of two long-acting insulin analogs (Table 2). Pooled analysis on treatment-related adverse events or withdrawal a result of adverse events was not possible because of insufficient data.
| Outcome title                          | No. studies | No. participants | Statistical method | Effect size                  | P-value | Test for heterogeneity | Test for effect I² (%) |
|---------------------------------------|-------------|------------------|--------------------|-----------------------------|---------|------------------------|--------------------------|
| Change in fasting glucose (mmol/L)    |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs rapid-acting insulin analogs | 3           | 470 vs 481       | WMD (95% CI)       | −1.36 (−3.21, 0.49)         | 0.15    | 97.2                   |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 4           | 1311 vs 1289     | WMD (95% CI)       | −0.57 (−1.29, 0.14)         | 0.11    | 87.2                   |                          |
| Long-acting insulin analogs vs human NPH insulin | 6           | 1206 vs 1246     | WMD (95% CI)       | −0.20 (−0.38, −0.02)        | 0.03    | 0                      |                          |
| Long-acting insulin analogs vs GLP-1 analogs | 4           | 468 vs 484       | WMD (95% CI)       | −1.35 (−1.64, −1.06)        | <0.0001 | 0                      |                          |
| Change in postprandial glucose (mmol/L) |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs rapid-acting insulin analogs | 3           | 465 vs 478       | WMD (95% CI)       | 0.78 (0.38, 1.19)           | 0.0001  | 5.3                    |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 3           | 398 vs 390       | WMD (95% CI)       | −0.52 (−1.25, 0.21)         | 0.17    | 67.3                   |                          |
| Change in weight (kg)                 |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs rapid-acting insulin analogs | 3           | 465 vs 478       | WMD (95% CI)       | −1.57 (−3.01, 0.13)         | 0.03    | 73.3                   |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 4           | 1311 vs 1289     | WMD (95% CI)       | −1.25 (−1.64, −0.87)        | <0.0001 | 5.3                    |                          |
| Long-acting insulin analogs vs human NPH insulin | 6           | 1208 vs 1199     | WMD (95% CI)       | −0.32 (−1.10, 0.45)         | 0.41    | 63                     |                          |
| Long-acting insulin analogs vs GLP-1 analogs | 5           | 688 vs 696       | WMD (95% CI)       | 4.12 (3.25, 4.99)           | <0.0001 | 748                    |                          |
| Daily insulin doses by bodyweight (U/kg) |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs rapid-acting insulin analogs | 2           | 279 vs 287       | WMD (95% CI)       | −0.01 (−0.16, 0.14)         | 0.91    | 59.7                   |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 6           | 1646 vs 1617     | WMD (95% CI)       | −0.07 (−0.14, 0.00)         | 0.04    | 87.2                   |                          |
| Long-acting insulin analogs vs human NPH insulin | 5           | 896 vs 925       | WMD (95% CI)       | 0.03 (0.01, 0.06)           | 0.01    | 99.3                   |                          |
| Incidence of total hypoglycemia (%)   |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs rapid-acting insulin analogs | 3           | 465 vs 478       | OR (95% CI)        | 0.23 (0.05, 1.13)           | 0.07    | 91.2                   |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 6           | 1789 vs 1759     | OR (95% CI)        | 0.72 (0.56, 0.94)           | 0.01    | 61.2                   |                          |
| Long-acting insulin analogs vs human NPH insulin | 6           | 998 vs 999       | OR (95% CI)        | 0.57 (0.45, 0.72)           | <0.0001 | 30.3                   |                          |
| Incidence of severe hypoglycemia (%)  |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 3           | 1265 vs 1231     | OR (95% CI)        | 0.62 (0.31, 1.21)           | 0.16    | 0                      |                          |
| Long-acting insulin analogs vs human NPH insulin | 5           | 1185 vs 1235     | OR (95% CI)        | 0.78 (0.45, 1.35)           | 0.57    | 20.8                   |                          |
| Long-acting insulin analogs vs GLP-1 analog | 3           | 423 vs 429       | OR (95% CI)        | 1.55 (0.37, 6.57)           | 0.55    | 55.8                   |                          |
| Incidence of nocturnal hypoglycemia (%) |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 3           | 1256 vs 1237     | OR (95% CI)        | 0.99 (0.84, 1.16)           | 0.89    | 0                      |                          |
| Long-acting insulin analogs vs human NPH insulin | 4           | 851 vs 878       | OR (95% CI)        | 0.46 (0.37, 0.58)           | <0.0001 | 0                      |                          |
| Incidence of any adverse events (%)   |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs rapid-acting insulin analogs | 3           | 465 vs 478       | OR (95% CI)        | 1.51 (0.65, 3.50)           | 0.33    | 65.6                   |                          |
| Long-acting insulin analogs vs biphasic insulin analogs | 3           | 1372 vs 1348     | OR (95% CI)        | 0.78 (0.60, 1.02)           | 0.07    | 0                      |                          |
| Long-acting insulin analogs vs human NPH insulin | 4           | 648 vs 654       | OR (95% CI)        | 0.86 (0.67, 1.11)           | 0.25    | 19.6                   |                          |
| Long-acting insulin analogs vs GLP-1 analog | 3           | 430 vs 436       | OR (95% CI)        | 0.33 (0.13, 0.85)           | 0.02    | 84                     |                          |
| Incidence of treatment related adverse events (%) |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs human NPH insulin | 3           | 646 vs 667       | OR (95% CI)        | 1.23 (0.82, 1.86)           | 0.32    | 6.3                    |                          |
| Long-acting insulin analogs vs GLP-1 analog | 3           | 430 vs 436       | OR (95% CI)        | 0.04 (0.03, 0.06)           | <0.0001 | 0                      |                          |
| Withdrawal due to adverse events (%)  |             |                  |                    |                             |         |                        |                          |
| Long-acting insulin analogs vs human NPH insulin | 3           | 672 vs 701       | OR (95% CI)        | 0.68 (0.27, 1.67)           | 0.39    | 0                      |                          |
| Long-acting insulin analogs vs GLP-1 analog | 4           | 460 vs 466       | OR (95% CI)        | 0.19 (0.05, 0.66)           | 0.009   | 37.9                   |                          |

GLP-1, glucagon-like peptide-1; NPH, neutral protamine Hagedorn; WMD, weighted mean differences.
Long-acting Insulin Analogs vs Biphasic Insulin Analogs

HbA1c
Pooling studies showed that long-acting insulin analogs were less effective than biphasic insulin analogs in decreasing HbA1c (WMD 0.19%, 95% CI 0.04–0.34; Figure 2b), but this effect varied between studies \(^{11,16,18,19}\). Heterogeneity was substantially reduced when a study with shorter diabetes duration and lower baseline HbA1c was removed (WMD 0.11%, 95% CI 0.02–0.19; \(I^2 = 0\%\))\(^{16}\). The SD for change in three studies were calculated, in which two studies were imputed from 95% CI and \(P\)-values for the difference in means\(^{11–19}\), and the other study was imputed from the baseline and final SD\(^{19}\).

Fasting Glucose and Postprandial Glucose
Pooling studies showed that long-acting insulin analogs were not statistically significant to biphasic insulin analogs in decreasing fasting glucose (WMD \(-0.57\) mmol/L, 95% CI \(-1.29\) to 0.14\(^{11,16,18,19}\) and morning postprandial glucose (WMD \(-0.52\) mmol/L, 95% CI \(-1.25\) to 0.21\(^{11,16,19}\), but with high heterogeneity (fasting glucose \(I^2 = 87.2\%\); postprandial glucose \(I^2 = 67.3\%\); Table 2). Heterogeneity in fasting glucose or postprandial glucose was not explained by baseline HbA1c levels or combination therapy of OHA or the treatment target. The SD for change in two studies were calculated from the baseline and final SD\(^{18,19}\).

Weight Gain
Pooling citations showed that long-acting insulin analogs, long-acting insulin analogs were significantly associated with less weight gain (WMD \(-0.12\) kg, 95% CI \(-0.64\) to \(-0.87\)), the effect was not heterogeneous \((I^2 = 5.3\%\); Table 2\(^{11,16,18,19}\).

Daily Insulin Dose by Bodyweight
Pooling studies showed daily insulin dosages by bodyweight in long-acting insulin analogs group were lower than those in biphasic insulin analogs group (WMD \(-0.07\) IU/kg per day, 95% CI \(-0.14\) to 0.00), but with heterogeneity \((I^2 = 87.2\%\); Table 2\(^{11,16,18,19}\).

Hypoglycemia
Pooling studies showed that long-acting insulin analogs were associated with a lower incidence of total hypoglycemia compared with biphasic insulin analogs (OR 0.72, 95% CI 0.56–0.94), but this was highly varied \((I^2 = 61.2\%\); Table 2\(^{11,16,19}\). Heterogeneity was substantially reduced when a study with higher baseline HbA1c (9.77%) was removed (OR 0.82, 95% CI 0.71–0.94; \(I^2 = 0\%\))\(^{19}\). Pooling studies reported a non-significant difference in incidence of nocturnal hypoglycemia (OR 0.99, 95% CI 0.84–1.16\(^{18,20,21}\) and severe hypoglycemia (OR 0.62, 95% CI 0.31–1.21\(^{17–19}\) between two treatment arms, the effects were not heterogeneous for both comparisons \((I^2 = 0\%\); Table 2\(^{11,16,18,19}\).

Adverse Events
Pooling three studies showed no significant difference in incidence of any adverse events between long-acting and biphasic insulin analogs (OR 0.78, 95% CI 0.60–1.02) (Table 2\(^{11,17,18}\). Pooled analysis on treatment-related adverse events or withdrawal as a result of adverse events was not possible because of insufficient data.

Long-acting Insulin Analogs vs Intermediate-acting Human NPH Insulin

HbA1c
Pooling studies showed that change of HbA1c from baseline to study end-point was not statistically significant between two treatment arms (WMD \(-0.02\%\), 95% CI \(-0.11\) to 0.07; Figure 2c), the effect was not heterogeneous between studies \((I^2 = 36.3\%)\(^{22–30}\). The SD of change in six studies were imputed from baseline and final SD\(^{23,25,27–30}\).

Fasting Glucose and Postprandial Glucose
Pooling citations showed that long-acting insulin analogs were superior in decreasing fasting glucose compared with NPH insulin (WMD \(-0.20\) mmol/L, 95% CI \(-0.38\) to \(-0.02\)), the effect was not heterogeneous \((I^2 = 0\%\); Table 2\(^{25–30}\). Heterogeneity was substantially reduced when two studies with detemir were removed (WMD 0.16 kg, 95% CI \(-0.25\) to 0.56; \(I^2 = 0\%\))\(^{26,27}\). Furthermore, pooling these two citations with detemir showed that detemir has less weight gain than NPH (WMD \(-1.26\) kg, 95% CI \(-1.70\) to \(-0.83\)), but with high heterogeneity \((I^2 = 60\%\))\(^{26,27}\). The SD for change in two studies were calculated from 95% CI and \(P\)-values for the difference in means\(^{26,27}\).

Daily Insulin Dose by Bodyweight
Pooling studies showed daily insulin dosages by bodyweight in the long-acting insulin analogs group were higher than those in the NPH insulin group (WMD 0.03 IU/kg per day, 95% CI 0.01–0.06), but with heterogeneity \((I^2 = 99.3\%\); Table 2\(^{22,24,26,28,30}\).

Hypoglycemia
Pooling citations showed that long-acting insulin analogs were associated with a lower incidence of total hypoglycemia compared with NPH insulin (OR 0.57, 95% CI 0.45–0.72\(^{24–27,29}\) and nocturnal hypoglycemia\(^{24,26,27,29}\) (OR 0.46, 95% CI 0.37–0.58) compared with NPH insulin; both the effect estimates were not heterogeneous \((I^2 = 30.3\%\) for total hypoglycemia and \(I^2 = 0\%\) for nocturnal hypoglycemia). Pooling citations reported a non-significant difference in incidence of severe hypoglycemia between two arms (OR 0.78, 95% CI 0.45–1.35), the effect was not heterogeneous \((I^2 = 20.8\%\); Table 2\(^{24,26–29}\).
**Adverse Events**

Pooling citations showed a non-significant difference in any adverse events (OR 0.86, 95% CI 0.67–1.11)\(^2\)\(^3\)–\(^2\)\(^6\), treatment-related adverse events (OR 1.23, 95% CI 0.82–1.86)\(^2\)\(^3\)–\(^2\)\(^7\), and withdrawal as a result of adverse events (OR 0.68, 95% CI 0.27–1.67)\(^2\)\(^3\)–\(^2\)\(^9\) between long-acting insulin analogs and NPH insulin. The effects were not heterogeneous for all these outcomes (any adverse events \(I^2 = 19.6\%\); treatment-related adverse events \(I^2 = 6.3\%\); withdrawal as a result of adverse events, \(I^2 = 0\%\); Table 2).

**Long-acting Insulin Analog vs GLP-1 Analogs**

**HbA\(_1c\)**

Pooling citations showed a non-significant difference in change of HbA\(_1c\) from baseline to study end-point between two treatment arms (WMD -0.05%, 95% CI -0.05 to 0.15), the effect was not heterogeneous (\(I^2 = 0\%\); Figure 2d)\(^3\)\(^1\)–\(^3\)\(^5\). The SD of change in one study were imputed from 95% CI for differences in means\(^3\)\(^5\).

**Fasting Glucose and Postprandial Glucose**

Pooling four citations showed that long-acting insulin analog was superior in decreasing fasting glucose (WMD -1.35 mmol/L, 95% CI -1.64 to -1.06) than GLP-1 analogs, the effect was not heterogeneous (\(I^2 = 0\%\); Table 2)\(^3\)\(^1\)–\(^3\)\(^5\). Pooled analysis on postprandial glucose was not possible as a result of lack of data.

**Weight Change**

Pooling five citations showed that, compared with GLP-1 analogs, long-acting insulin analog was associated with greater weight gain (WMD 4.12 kg, 95% CI 3.25–4.99), but with high heterogeneity (\(I^2 = 74.8\%\); Table 3)\(^3\)\(^1\)–\(^3\)\(^5\). Heterogeneity was reduced when a study with higher starting body mass index was removed (WMD 3.81 kg, 95% CI 3.39–4.23; \(I^2 = 35.3\%\))\(^3\)\(^1\). The SD for change in one study were calculated from 95% CI and \(P\)-values for the difference in means\(^3\)\(^5\).

**Hypoglycemia**

Pooled analysis on total or nocturnal hypoglycemia was not possible as a result of different units between studies. Four studies reported no differences in the episode or incidence or event of total hypoglycemia between two treatment arms\(^3\)\(^1\)–\(^3\)\(^5\), One study reported that hypoglycemia was more frequent in the glargine group (24.2 vs 8.3%, \(P\)-value was not shown)\(^3\)\(^8\). In addition, three citations reported GLP-1 analogs were significantly associated with a lower risk of nocturnal hypoglycemia than long-acting insulin analogs\(^3\)\(^2\),\(^3\)\(^3\),\(^3\)\(^5\). Pooling citations reported no difference in severe hypoglycemia between two treatment arms (OR 1.55, 95% CI 0.37–6.57), but with high heterogeneity (\(I^2 = 55.8\%\); Table 2)\(^3\)\(^1\)–\(^3\)\(^5\). Heterogeneity was reduced (OR 0.89, 95CI 0.36–2.23; \(I^2 = 0\%\)) when a study with higher duration and baseline HbA\(_1c\) was removed\(^3\)\(^4\).

**Efficacy of long-acting insulin analogs**

**Adverse Events**

Pooling citations showed that, compared with GLP-1 analogs, long-acting insulin analog was associated with less incidence of any adverse events (OR 0.33, 95% CI 0.13–0.85)\(^3\)\(^1\),\(^3\)\(^4\),\(^3\)\(^5\), treatment-related adverse events (OR 0.04, 95% CI 0.03–0.06)\(^3\)\(^1\),\(^3\)\(^4\),\(^3\)\(^5\), and withdrawal as a result of adverse events (OR 0.19, 95% CI 0.05–0.66)\(^3\)\(^1\),\(^3\)\(^2\),\(^3\)\(^4\),\(^3\)\(^5\). The effect estimates were heterogeneous for any adverse events (\(I^2 = 84\%\)), but not heterogeneous for treatment-related adverse events and withdrawal as a result of adverse events (treatment-related adverse events \(I^2 = 0\%\); withdrawal as a result of adverse events \(I^2 = 37.9\%\); Table 2).

**DISCUSSION**

We found that all the included preparations helped to keep reducing HbA\(_1c\) levels by an average of 1.1–1.6% with 29–72 weeks follow up. Long-acting insulin analogs-based regimens were not statistically significant to rapid-acting insulin analogs or NPH insulin or GLP-1 analogs-based regimens in terms of decreasing HbA\(_1c\). Where there were statistical differences between long-acting insulin analogs and biphasic insulin analogs-based regimens in decreasing HbA\(_1c\), the differences (0.19%) were sufficiently small to have minimal if any clinical significance.

We observed that the clinical benefits of long-acting insulin analogs were associated with less weight gain over biphasic insulin analogs. The superiority in less weight gain of long-acting insulin analogs over rapid-acting insulin analogs was inconsistent as a result of heterogeneity. Pooling analysis on studies with detemir or glargine noted that detemir, but not glargine, was associated with less weight gain over NPH insulin, consistent with other reviews\(^3\)\(^6\),\(^3\)\(^7\). Long-acting insulin analogs were associated with greater weight gain in comparison with GLP-1 analogs.

As well, we found clinical advantages for long-acting insulin analogs over biphasic insulin analogs in the incidence of total hypoglycemia. Long-acting insulin analogs were associated with a lower incidence of total hypoglycemia and nocturnal hypoglycemia over NPH insulin.

In addition, long-acting insulin analogs were superior to GLP-1 analogs in fewer risks of any adverse events, treatment related adverse events and withdrawal as a result of adverse events. It should be stated that many of the treatment-related adverse events with GLP-1 analogs are related to gastrointestinal side-effects, notably nausea, vomiting and diarrhea. The pooled analysis on micro- and macrovascular complications was not possible, because no study evaluated these long-term outcomes.

These results are important, because the aim of early intensive treatment is glycemic control without induction of hypoglycemia or weight gain, and in the long-term, reduction in micro- and macrovascular complications. UKPDS showed that a lower 0.9% of HbA\(_1c\) value was associated with a reduced 25% (\(P = 0.0099\)) risk of microvascular complications and a reduced 16% (\(P = 0.052\)) risk of myocardial infarction compared with conventional therapy\(^3\)\(^8\). This suggests that reduced HbA\(_1c\) levels by an average of 1.1–1.6% in our analyses might well equate to
significantly reduced risks of complications. The difference between long-acting insulin analogs and biphasic insulin analogs appeared to be slight (0.19%), and the difference for subgroup analysis after removing heterogeneity was even less (0.11%). There are insufficient data to determine whether marginal reduction in HbA1c is of benefit in reducing diabetes-related complications. It has, however, been reviewed by us and others that biphasic insulin decreased HbA1c level at the expense of an increased risk of total hypoglycemia and more weight gain. It seems likely that long-acting insulin initiation by means of one injection might facilitate patients’ acceptance of insulin initiation.

Inconsistent with our findings to some extent, previous reviews observed that a greater reduction of 0.45% in HbA1c was seen for biphasic and prandial insulin-based regimens compared with basal insulin based on regimens in type 2 diabetics failing on OHA. Given the weight of the 4-T study in the meta-analysis, these findings could be partly explained by the included 3-year results, in which the superiority of the prandial and biphasic insulin relative to basal insulin at 1-year disappeared or decreased. The difference emphasizes the need to carry out long-term, high-quality studies specifically designed to determine the clinical outcomes, which are particularly important in the setting of chronic disease, such as type 2 diabetes.

The present study had limitations. The ability to understand the heterogeneity for all comparisons remains limited as a result of a small number of studies and variations in quality of studies. To address this limitation, a random-effects model was used for analysis regardless of the presence or absence of statistical heterogeneity. The small number of studies also limited our ability to fully address the potential publication bias. Furthermore, we included studies that included both crossover and parallel designs. These might be the potential sources of heterogeneity of findings. However, it did reflect the state of clinical research in this area; and consistent with our findings, previous reviews also had such methodological limitations.

In conclusion, for insulin-naïve patients with type 2 diabetes failing on oral agents, initiating long-acting insulin analogs seems likely to provide glycemic control similar to rapid-acting insulin analogs or NPH insulin or GLP-1 analogs and is marginally inferior in glycemic control compared with biphasic insulin analogs with fewer side-effects. High-quality studies are needed to evaluate the long-term effects of insulin preparations on clinical outcomes.

ACKNOWLEDGMENTS
This work was supported by grants from The Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China Grant Award (30800539, 81070636, 8107049), the Ministry of Health of the People’s Republic of China for Key Projects of Clinical Disciplines of Hospitals Affiliated to Ministry of Health (2010–2012), Program for Changjiang Scholars and Innovative Research Team in University (985 project IRT0947), Sun Yat-Sen University Clinical Research 5010 Program (2007-2017). No conflict of interest exists with this research.

REFERENCES
1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.
2. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
3. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765–1772.
4. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–1258.
5. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102–110.
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
7. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Rev 2008; 6: 54–67.
8. Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009; 52: 1990–2000.
9. Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 549–559.
10. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716–1730.
11. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736–1747.
12. Wagner AM, Mauricio D. Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions? Diabetologia 2010; 53: 1004–1005.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta analysis. Stat Med 2002; 21: 1539–1558.
15. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine vs thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents.
(APOLLO): an open randomised controlled trial. *Lancet* 2008; 371: 1073–1084.

16. Kazda C, Hulstunik H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. *J Diabetes Complications* 2006; 20: 145–152.

17. Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 vs insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational, RCT. *Curr Med Res Opin* 2009; 25: 2887–2894.

18. Buse JB, Wollffenbuttel BH, Herman WH, et al. Durability of basal vs lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 vs insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. *Diabetes Care* 2009; 32: 1007–1013.

19. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005; 28: 260–265.

20. Malone JK, Kerr LF, Campagna BN, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. *Clin Ther* 2004; 26: 20340–20440.

21. Study NCT00377858. Comparison of Otwo Approaches to insulin therapy in patients with type 2 diabetes. Available: http://www.clinicaltrials.gov (last assessed on 2010, March 20).

22. DeMattia G, Laurenti O, Moretti A. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. *Acta Diabetologica* 2009; 46: 67–73.

23. Pan CY, Sinnaarsmy P, Chung KD, et al. Insulin glargine vs NPH insulin therapy in Asian Type 2 diabetes patients. *Diabetes Res Clin Pract* 2007; 76: 111–118.

24. Elíaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. *Arch Med Res* 2006; 37: 495–501.

25. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LAMNET study. *Diabetologia* 2006; 49: 442–451.

26. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther* 2006; 28: 1569–1581.

27. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care* 2006; 29: 1269–1274.

28. Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003; 26: 3080–3086.

29. Fritzsche A, Schweitzer MA, Häring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. *Ann Intern Med* 2003; 138: 952–959.

30. Yki-Järvinen H, Dressler A, Ziemen Mm, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. *Diabetes Care* 2000; 23: 1130–1136.

31. Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes Obes Metab* 2009; 11: 1153–1162.

32. Bunck MC, Diamant M, Cornèr A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care* 2009; 32: 762–768.

33. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia* 2009; 52: 2046–2055.

34. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther* 2007; 29: 2333–2348.

35. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide vs insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2005; 143: 559–569.

36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352: 837–853.

37. Swinnen SG, Hoekstra JB, DeVries JH. Insulin Therapy for Type 2 Diabetes. *Lancet* 2005; 365: 371: 1073–1084.